Starting at any point, from Long Covid to onset infection, VEDICINALS® 9 can stop disease progression and accelerate recovery.
Please download your copy of presentation slides presented by Mr. Joachim Gerlach, at World Council for Health - Weekly General Assembly 17th January 2022.
Topic of Webinar : Comprehensive Protocol Targeting Acute & Long Covid Conditions
VEDICINALS® 9 Is an unique scientifically researched & proven therapeutic suspension that consist of nine bioactive compounds whose molecules have a track record of possessing various antiviral, anti-inflammatory, immune modulatory, anti-pyretic and analgesic properties, all with hundreds of supporting studies published in well-known credible peer reviewed scientific and medical journals.
The results from the various studies and even from new constant emerging data, shows that Vedicinals 9 is an upcoming therapeutic to help not only with the current COVID-19 pandemic but also in the long term health conditions associated with Post / Long COVID.
VEDICINALS®️ 9 has been approved as a food supplement Nutraceutical and as FSMP (Food for Special Medical Purpose) by the Food Safety And Standards Authority of India (FSSAI) and as a result of significant findings from a completed randomized Phase II clinical trial for its use as an adjuvant alongside standard treatment protocols for the treatment of mild and moderate COVID-19 hospitalized patients.
Here you find a detailed description of the 9 Bioactive molecules used in VEDICINALS® 9 and their documented efficacy against SARS-CoV-2 Coronavirus and Covid19 disease. Bioactive Molecules like Baicalin, Quercetin, Luteolin, Rutin, Hesperedin Curcumin, Epigallocatechin Gallate, Piperine, Glycyrrhizin.
All above constituents found in VEDICINALS® 9 were carefully selected for their various potential bioactivities against the SARS-CoV-2 coronavirus and also in addressing and helping to treat and regulate more than 71 human host cellular pathways that are disrupted by the virus directly or indirectly.
At the early stage of the COVID-19 pandemic Vedicinals’s research teams started detailed meta-analysis of past studies of various therapeutic molecules, computational docking studies and also developed a scientific rationale that would ensure the best possible outcomes leading to a COVID-19 therapeutic formulation.
The observation that COVID-19 is a multi -systemic condition with various degrees of disease severity and affects various body regions, with little influence on which state of disease progression therapeutic intervention was initiated added intense complexity to the tasks of developing a truly effective therapeutic.
However, we circumvented all obstacles by developing a strategy that focused on addressing the various identified desired drug target pathways.
This identified list of confirmed and possible drug target pathways was then used as a multiple selection criteria for the most potent molecules, in most cases each molecule covering multiple target pathways.
The initially identified 612 plus molecule candidates were then submitted to an advanced selection process that would take several additional criteria into consideration, like: past experience and data on potency, side effects, drug interactions bioavailability, synergies between the combined compounds, large scale availability of raw materials in the region and many other important criteria.
Most of our extensive research work was based on available global meta-analysis of existing in vivo human and animal studies, as well as cell culture studies and access to critical published data.
This formed the basis for further preclinical, toxicity, and human clinical trial evaluations that confirmed all previous research with excellent treatment outcomes.
The findings of the retrospective randomized clinical study demonstrate a promising role of VEDICINALS® 9 as an adjuvant to SOC therapy for COVID-19. It was found to help curtailing symptoms, preventing disease progression and strengthening the natural defences of the human host and also was found to aid in various post COVID-19 secondary complication. Know More
Although all patients were randomly selected, the patients in the VEDICINALS® 9 treatment group showed at onset of trial a much higher percentage of abnormal lung x-ray findings, probably by coincidence. The observed improvements, when compared to Standard Treatment Group are very remarkable.
X-Ray findings of COVID-19 positive patients from day 0 to 45. Data interpret following: Percentage of COVID-19 positive patients from day 0 to day 45, when vedicinals9 5000mg adjuvant to SOC with standard intervention compared with standard intervention alone.
Data represented as percentage of patients with abnormal findings of X-ray in two comparable interventional group (n=62 per group).
In the Myocardial infarction study, the results were remarkable in the sense that not only were there no adverse events or conditions reported from high dose application, there was actually data showing that VEDICINALS® 9 provided cardio protective benefits including significant protection of heart muscle tissues, blood vessels and the cardiovascular system.Know More
The following white paper details the 9 bioactive molecules used in formulating VEDICINALS® 9 including their properties, meta-analysis of past published studies and their specified drug targets and along with the manners that they individually rectify the disruptions in various human host cellular pathways caused by the SARS-CoV-2 coronavirus.Know More
Our scientific in silico teams were conducting close to 400 individual molecular docking analysis on all described drug target pathways. Included in this section are all relevant results of VEDICINALS® 9 against the new mutations and variants of SARS-COV-2.
Answer : Yes !! Most of the molecules in VEDICINALS® 9 would work well on all varients Delta, Delta+, Lambda ?
VEDICINALS® 9 has been approved as a food supplement cum Nutraceutical, FSMP by the Food Safety And Standards Authority of India (FSSAI) and as a result of extreme positive findings from a completed randomized clinical trial for its use as an adjuvant alongside standard treatment protocols for the treatment of mild and moderate COVID-19 hospitalized patients, it is being registered as a medical/pharmaceutical product.
VEDICINALS® 9 will also be going for filing for regulatory approvals in a number of countries including Malaysia, Singapore, Thailand, Australia, Canada, United States, Germany, Japan, Argentina, Brazil and Columbia in coming weeks.
VEDICINALS® 9 has gone thru stringent safety studies and protocols including animal studies. Although we highly recommend using it under the supervision of a licensed medical doctor, it is safe enough for an individual who suspect that they might already been infected with the SARS-CoV-2 or have tested positive for COVID-19 to immediately start taking the therapeutic suspensions as per dosing instructions found on the accompanying product leaflet.
Clinical trial data confirmed the prophylactic role of Vedicinals 9 on preventing Long Covid conditions.
Both factors, like arresting disease progression, as well as tissue regeneration could be documented.
As VEDICINALS®️ 9 is mainly designed to block human cells against virus entry,as well as interrupting the replication within the cells, we are confident that newly occurring variants can be stopped equally well, like in our last human clinical trials.
Additionally our scientists are constantly checking the efficacy against all upcoming variants.
As in general Covid19 conditions causes a decrease in zinc-serum levels,
past trials found it beneficial to add FSSAI recommended daily dosage of zinc supplementation.
Presently in India VEDICINALS®️ 9 is available online through our website as long as stock lasts. We are also exploring distribution partners and trying to make VEDICINALS®️ 9 available with leading pharmacies, clinics and certain hospitals throughout India. For exports we are going to start soon with countries Malaysia, Singapore, Thailand, Australia, Canada, United States, Germany, Japan, Argentina, Brazil and Columbia and expand worldwide. Please contact us on email firstname.lastname@example.org for overseas market along with your detailed profile and country / region of interest.
Yes, after you have purchased VEDICINALS®️ 9 , Please email / whats'app us with your invoice number. We are also working on and soon we will issue/send you a code/ link to sign-in to our existing customer’s sub-domain where there is a forum for all other customers to share their feedback and also a live chat area to seek any advice related to VEDICINALS®️ 9 only. We are also planning a CRM module where existing customers can also benefit from a wide variety of discounts and promotions related to the healthcare industry.
The recommended dosing is 25 mL (Half Bottle) 2x times per day, in total 50 mL per day for an Adult.
VEDICINALS® 9 suspension is best taken immediately after meals. If possible, please have minimum of 1 tablespoon of rice in meal.
Viral infections and antibiotics damage the gut micribiome. Ingesting prebiotics before meal helps balance gut microbiome and aids in metabolization of the food and VEDICINALS® 9 suspension. Fresh Curd or pre-packed probiotics available at pharmacies are best recommended.
Presently we claim that is has a shelf life of 18 months. The formulation was developed and manufactured at a GMP approved site and present evaluation has showed stability and this study will continue till 24 months.
VEDICINALS® is a German-Indian biotech company incorporated in Pune, India that is proud to introduce a new innovative therapeutic product that is clinically proven and extensively researched to serve as an adjuvant to SOC to treat COVID-19.
The early alliance with Tirupati Lifesciences Pvt. Ltd was the key to the professional development of this therapeutic formulation.
The combined efforts of Vedicinals India Pvt Ltd’s scientific international development teams and the long lasting experience of Tirupati Lifesciences Pvt. Ltd in practical formulation, quality control and production lead to this highly efficient and safe therapeutic product.
The Board consists of a group of highly accomplished professionals from public, private and development sector who share a common passion for social contribution focusing on working in close collaboration with other development partners. For more information on board & staff members, Please click on Know Board & Staff button.
Managing Director & Share holder
Head of Clinical Research
Head of In Silico and Documentation
Head of Pre Clinical Research
To begin with VEDICINALS®️ 9 Suspension was certified as Nutraceutical by FSSAI , Now upgraded to FSMP (Food for Specific Medical Purpose)
Disclaimer : All statements and claims have not been evaluated by any regulatory agency.
This website is not intended to diagnose, treat,cure or prevent any disease.
Our Father, who art in heaven,
hallowed be Thy name.
Our kingdom come
Thy will be done,
as it is in heaven,
so on earth.
Our daily bread you give us today,
And you forgive us our trespasses,
as we forgive those who trespass against us.
You lead us in temptation
and deliver us from evil,
for ours is the kingdom and the
power and the glory for ever and ever.